The information, however, is not in the label because the drug — originally manufactured by Merck — was never fully tested in this population. And the company has refused to update the language.

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

Merck's Vaxneuvance – formerly known as V114 – is the first major competition to Pfizer's franchise in the big market for conjugate pneumococcal vaccines ... with its off-label use.

This year, pharmaceutical giant Merck (NYSE: MRK ... such as its pair of HPV vaccines, Gardasil and Gardasil 9. Further, the ...

Welcome to the Merck & Company Q3 sales and earnings conference call. [Operator instructions] This call is being recorded.

Pivotal Phase 3 trial (IOB-013/KN-D18) evaluating off-the-shelf therapeutic cancer vaccine IO102-IO103 in combination with Merck’s anti-PD-1 ...

Merck reports Q3 sales of $16.7 billion, up 4% year-over-year, with Keytruda revenue rising 17%. EPS beats estimates; 2024 guidance updated on global demand shifts.

The information, however, is not in the label because the drug — originally manufactured by Merck — was never fully tested in this population. And the company has refused to update the language.

Merck will face an important patent cliff by ... such as its pair of HPV vaccines, Gardasil and Gardasil 9. Further, the company has a deep pipeline, with more than 80 programs in phase 2 studies ...